Thrombolytic Science, LLC (TSI) is a privately-held vascular health and biotechnology company leading development of a next-generation, life-saving therapy to transform traditional medical ...

US Patents Complement Existing Patent Protection in the US, Europe, Japan, and China CAMBRIDGE, MA, January 05, 2022 / B3C newswire / -- Thrombolytic Science, LLC (TSI) has been granted a second ...

Uniquely, the thrombolytic activity of BB-031 is designed to be quickly neutralized in the event of bleeding using a complementary agent, BB-025, which Basking is developing in tandem.